| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |